Tackling autoimmune disease by targeting Fc receptors

FcR Therapeutics is developing first-in-class antibody solutions for autoimmune disease.

We believe that our proprietary drug leads can target Fc receptors (FcRs), a specific class of receptors expressed on various immune cells, to provide a major therapeutic perspective for patients suffering from various devastating autoimmune diseases.

Background

Autoimmune diseases have a complex pathophysiology with various abnormalities involving all the components of the immune system. Among these components, antibodies against self-antigens are key contributors of autoimmunity.

Normal interplay between antibody and FcRs on immune cells can activate effector mechanism such as:

  • Antibody-dependent cell-mediated killing (ADCC) of antibody-coated target cells
  • Secretion of pro-inflammatory mediators
  • Phagocytosis of target cells
  • Enhanced antigen presentation

These powerful effector responses can be dysregulated by immune complexed autoantibodies resulting in major, tissue-destroying inflammation throughout the body.

Current treatments are mostly focused on immunosuppressants and Ig replacement therapy, at FcR Therapeutics we are developing a safer and more potent solution.

Approach

FcR Therapeutics provides proprietary antibody solutions aiming to disrupt the overactive interplay between autoantibodies and Fc receptors resulting in inflammation and tissue damage.

Our therapeutic focus is on autoimmune diseases that can benefit from interfering with derailed Fc-receptor biology by developing a risk-balanced and diverse pipeline of unique proprietary drugs, resulting in potent and safe therapeutic options.

Team

FcR Therapeutics is founded and led by a team of experienced drug developers, antibody experts and seasoned entrepreneurs.

Mark de Boer, PhD

Chief Executive Officer

Geert van Tetering, PhD

Chief Operating Officer

Guido Maertens, MSc

Chief Financial Officer

News

Barcelona, February 4, 2025

Grifols Teams Up with FcR Therapeutics to Pioneer Recombinant Autoimmune Therapies

Grifols, a global leader in plasma-derived medicines and immunological research, has announced a strategic early-stage collaboration with Utrecht-based biotech startup FcR Therapeutics. The partnership aims to develop innovative recombinant nanobodies targeting Fc receptors, proteins that play a crucial role in triggering autoimmune diseases…

© FcR Therapeutics, 2025 | All rights reserved